Intermittent Pneumatic Compression for Disability Reversal in PAD: The INTERCEDE Study

Dr. Peterson will serve as co-investigator, subcontract director, and principal investigator of the University of Kentucky site, will be responsible for oversight and coordination of the staining and immunohistochemical analyses of muscle biopsies collected from participants in the INTERCEDE Trial at baseline and follow-up. Dr. Peterson will be responsible for providing oversight to muscle sample analyses in her laboratory (214 anticipated from baseline and follow-up). In Dr. Peterson’s laboratory, muscle samples will be analyzed for changes in immunohistochemistry-measured mitochondrial activity (COX and SDH), autophagy (LC3, LAMP2, and PARKIN), angiogenesis (CD31), satellite cell content (PAX7), and myofiber typing. Analyses will be performed in a blinded fashion and investigators will be unaware of the group assignment corresponding to any of the muscle specimens. Investigators will also be unaware of whether each muscle specimen is from baseline or follow-up during the measurement. Measures will be made in frozen human muscle biopsies shipped to the University of Kentucky from Northwestern University. There will be immunohistochemical analyses of muscle crosssections for 214 specimens in years three -five. Digital microscopic images, as well as quantification of the images, will be provided to investigators at Northwestern quarterly during years three through five. Dr. Peterson will communicate regularly with Dr. McDermott and other members of the investigative team throughout the study by phone, email and video conferencing. In year five, Dr. Peterson will participate in review and interpretation of the results and manuscript writing.